Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity?
Pfizer's strong Q2 results, high dividend yield, and bullish chart fuel optimism despite patent losses and rising competition.
Zacks·3d ago
More News
Pfizer Defends Transparency On COVID-19 Vaccine Data, Says Trump’s ‘Operation Warp Speed’ Effort Deserves Nobel Peace Prize
Pfizer lauded “Operation Warp Speed” for helping the country save over $1 trillion in healthcare costs due to a reduction in serious illnesses and subsequent hospitalizations.
Stocktwits·5d ago
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Zacks·5d ago
Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?
CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.
Zacks·6d ago
Pfizer's Golden Cross Signals Strength: How to Play the Stock
Pfizer trades above key SMAs with a golden cross, while new drugs and cost cuts drive growth despite looming headwinds.
Zacks·7d ago
Boyd Gaming and Shoe Carnival have been highlighted as Zacks Bull and Bear of the Day
Boyd Gaming surges on strong earnings and growth plans, while Shoe Carnival struggles with sliding sales and weaker momentum.
Zacks·10d ago
Marvell, Nvidia, Bank of America, Alphabet, Pfizer: What Sparked Heavy After-Hours Trading In These 5 Stocks?
Skepticism about the AI revolution gaining momentum has gained ground after Nvidia and Marvell reported soft data center sales.
Stocktwits·10d ago
FDA Approves Updated COVID-19 Vaccines but With Restrictions
FDA clears updated COVID-19 vaccines from Pfizer, Moderna and Novavax but limits access to older adults and high-risk groups.
Zacks·11d ago
MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate
Merck and Daiichi Sankyo begin dosing in the phase III HERTHENA-Breast04 study on patritumab deruxtecan in certain breast cancer patients.
Zacks·11d ago
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
ALNY's Amvuttra revenues surge with 89% sales growth in H1 and a key label expansion, but faces tough competition in the ATTR-CM market.